Disparities in Access to Novel Systemic Therapies in Patients With Urinary Tract Cancer: Propagating Access, Policies and Resources Uniformly
- 13 October 2022
- journal article
- research article
- Published by Elsevier in Clinical Genitourinary Cancer
- Vol. 21 (2) , 301-308
Abstract
No abstract availableKeywords
This publication has 21 references indexed in Scilit:
- A phase III randomized study of neoadjuvant chemotherapy (NAC) alone or in combination with nivolumab (NIVO) ± linrodostat mesylate, followed by adjuvant postsurgical NIVO ± linrodostat, in cisplatin-eligible muscle invasive bladder cancer (MIBC).Journal of Clinical Oncology, 2020
- Bladder Cancer, Version 3.2020, NCCN Clinical Practice Guidelines in OncologyJournal of the National Comprehensive Cancer Network, 2020
- Pivotal Trial of Enfortumab Vedotin in Urothelial Carcinoma After Platinum and Anti-Programmed Death 1/Programmed Death Ligand 1 TherapyJournal of Clinical Oncology, 2019
- Erdafitinib in Locally Advanced or Metastatic Urothelial CarcinomaNew England Journal of Medicine, 2019
- European Association of Urology Guidelines on Upper Urinary Tract Urothelial Carcinoma: 2017 UpdateEuropean Urology, 2018
- First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 studyThe Lancet Oncology, 2017
- Pembrolizumab as Second-Line Therapy for Advanced Urothelial CarcinomaNew England Journal of Medicine, 2017
- Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trialThe Lancet, 2017
- UPPER TRACT UROTHELIAL NEOPLASMS: INCIDENCE AND SURVIVAL DURING THE LAST 2 DECADESJournal of Urology, 2000
- What Makes Clinical Research Ethical?JAMA, 2000